FDA clears Michelson's VivoSight scanner
This article was originally published in Clinica
Michelson Diagnostics' VivoSight optical coherence tomography (OCT) scanner has received 510(k) clearance from the US FDA. The device uses the firm's patented multi-beam OCT technology to provide real-time, sub-surface images of tissue at “far higher” resolution than other imaging methods, including ultrasound, CT and MRI. The handheld probe can generate two- or three-dimensional images of the epidermis, dermis and sub-surface blood vessels. Orpington, UK-based Michelson CE marked the scanner for sale in Europe in October 2009. In November, the company received a £25,000 grant from the UK government’s Technology Strategy Board to help develop miniaturised probes for use with the scanner for cancer diagnosis (www.clinica.co.uk, November 26 2009).
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.